|
Summary of cardiac safety with trastuzumab in early breast cancer |
|||||
| TRIAL |
ARM |
Baseline LEVF(%) |
CHF(%) |
Cardiac death |
Cardiac follow-up |
|
|
|||||
| HERA |
NIL |
>= 55 |
0 |
1 |
MUGA scan or echocardiogram at 3–4 wks prior to randomization, and 3, 6, 12, 18, 24, 30, 36, and 60 mos from randomization |
| H 1 YEAR |
0.6 |
0 |
|||
| NSABP-31 |
AC followed P |
>= 50 |
0.8 |
1 |
MUGA scan or echocardiogram 3 wks after last AC dose, 6, 9, and 18 mos from randomization, and 3 mos after last trastuzumab dose |
| AC followed PH |
4.1 |
0 |
|||
| NCCTGN9831 |
AC followed P |
>= 50 |
0.3 |
1 |
MUGA scan 3 wks after last AC dose, 6 and 9 mos from randomization, and 3 mos after the last trastuzumab dose |
| AC followed P and H |
2.5 |
1 |
|||
| AC followed PH |
3.5 |
0 |
|||
| BCIRG006 |
AC followed D |
>= 50 |
0.3 |
0 |
After last AC dose, after second docetaxel dose, after end of chemotherapy, and at 3, 12 and 36 mos from randomization. At baseline, at 6 wks, 4.5 mos,13.5 mos, and 37.5 mos from randomization |
| AC followed DH |
1.6 |
0 |
|||
| DCarbo followed H |
0.4 |
0 |
|||
| FIN HER |
NO H |
>= 50 |
3 |
0 |
MUGA scan or echocardiogram before chemotherapy, after CEF, and 12 and 36 mos after completion of chemotherapy |
| H |
0 |
0 |
|||
|
AC, doxorubicin plus cyclophosphamide; BCIRG, Breast Cancer International ;NCCTG, North Central Cancer Treatment Group; NSABP, National Surgical Adjuvant Breast and Bowel Project; P, paclitaxel. MUGA, multigated acquisition;Research Group; Carbo, carboplatin;CHF, congestive heart failure; cum, cumulative incidence; D, docetaxel; H, trastuzumab; HERA, Herceptin® Adjuvant; LVEF, left ventricular ejection fraction; | |||||
Viani et al. BMC Cancer 2007 7:153 doi:10.1186/1471-2407-7-153 |
|||||